← Back to Clinical Trials
Recruiting NCT07299500

NCT07299500 Study of a Cohort of Non-HIV Immunocompromised Patients With Toxoplasmosis at the Strasbourg University Hospital

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07299500
Status Recruiting
Phase
Sponsor University Hospital, Strasbourg, France
Condition Cerebral Toxoplasmosis
Study Type OBSERVATIONAL
Enrollment 30 participants
Start Date 2025-02-02
Primary Completion 2026-02

Trial Parameters

Condition Cerebral Toxoplasmosis
Sponsor University Hospital, Strasbourg, France
Study Type OBSERVATIONAL
Phase N/A
Enrollment 30
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2025-02-02
Completion 2026-02

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Toxoplasmosis in HIV-positive individuals is well-studied and has a codified management protocol, which is not the case for other immunodeficiencies, except for recent recommendations in the context of hematopoietic stem cell transplantation. A description of this population is necessary to estimate the number of patients affected and to define their specific management (diagnosis, treatment, prevention).

Eligibility Criteria

Inclusion Criteria: * Adult (≥18 years) * Immunocompromised (i.e., solid organ transplant recipient, hematological malignancy, cancer patient, patient treated with immunosuppressive therapy or therapy affecting the immune system by any mechanism, hematopoietic stem cell transplant recipient, patient with an autoimmune disease or immunodeficiency, whether primary or secondary). * At least one positive toxoplasmosis PCR test (regardless of tissue) Exclusion Criteria: * Subject who has expressed opposition to the reuse of their data for scientific research. * HIV positive * Congenital toxoplasmosis * Isolated ocular toxoplasmosis in immunocompetent individuals

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology